Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05027776 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

StatusUnknown
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Apr 2024); last known: Recruiting
  2. Primary completion date changed from estimate of May 29, 2022 to Nov 22, 2023
    • Secondary endpoints: details revised at 1 of 6 entries
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Enrollment target: 1350 to 1348
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 24, 2021 to Sep 15, 2021
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years
Trial Details
NCT Number NCT05027776
Lead Sponsor Shanghai Bovax Biotechnology Co., Ltd.
Collaborators: Chongqing Bovax Biopharmaceutical Co., Ltd.
Conditions
(from sponsor)		 HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart, CIN1, CIN2, CIN3
Related terms Condylomata Acuminata, Papillomavirus Infections, Uterine Cervical Neoplasms, Vaginal Neoplasms
Enrollment 1,348 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov